<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379741</url>
  </required_header>
  <id_info>
    <org_study_id>A-14-1013-C-01</org_study_id>
    <nct_id>NCT02379741</nct_id>
  </id_info>
  <brief_title>ADC-1013 First-in-Human Study</brief_title>
  <official_title>A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally or Intravenously Administered ADC-1013</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alligator Bioscience AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alligator Bioscience AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ADC-1013 (an agonistic human monoclonal
      IgG1 anti-CD40 antibody) is safe and tolerable when administered intratumorally (as repeated
      injections directly into the tumor tissue) or intravenously (as repeated doses directly into
      a vein) in patients with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">March 8, 2017</completion_date>
  <primary_completion_date type="Actual">March 8, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of increasing doses of ADC-1013, assessed by medical review of AE reports and vital signs measurements (blood pressure, pulse rate, body temperature), physical examinations, ECGs and clinical laboratory tests.</measure>
    <time_frame>From start of study until end of study (appr 28 days after last dose)</time_frame>
    <description>Dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended Phase 2 dose of ADC-1013 administered intratumorally or intravenously will be defined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ADC-1013 after single and repeated administrations assessed by the following parameters: Cmax, Tmax, elimination half-life, AUC0-∞, total serum clearance (CL) and the volume of distribution at steady state (Vss).</measure>
    <time_frame>From first dose until 55 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of ADC-1013 after repeated administrations assessed by anti-drug antibody (ADA) titers in serum</measure>
    <time_frame>From first dose until end of study (appr 28 days after last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy (i.e. anti-tumor activity) of ADC-1013 assessed by immune-related RECIST (irRECIST) and RECIST 1.1.</measure>
    <time_frame>From start of study until end of study (appr 28 days after last dose)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Neoplasms</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ADC-1013 intratumoral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intratumoral injection every second week for 8 weeks. Patients that do not progress will be offered continued treatment until complete response, confirmed progressive disease, or clinical deterioration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADC-1013 intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intravenous infusion every second week until complete response, confirmed progressive disease, or clinical deterioration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADC-1013</intervention_name>
    <description>Agonistic human monoclonal IgG1 anti-CD40 antibody</description>
    <arm_group_label>ADC-1013 intratumoral</arm_group_label>
    <arm_group_label>ADC-1013 intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Diagnosis of advanced solid tumor disease

          -  Performance status of 0-1 on the ECOG scale

          -  Life expectancy of at least 3 months

        Major Exclusion Criteria:

          -  Organ transplant recipient

          -  Autoimmune disorder

          -  Other malignancy (except localized prostate cancer, adequately treated basal skin
             cancer or carcinoma in-situ of the cervix)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Norlén, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alligator Biosciene AB, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dorte Nielsen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Herlev Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Cancer Research, Department of Oncology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniska prövningsenheten (KPE), Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <state>Stockholm</state>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Queen Elisabeth Hospital</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre</name>
      <address>
        <city>Bebington</city>
        <state>Wirral</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibodies</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Antineoplastic agent</keyword>
  <keyword>Physiological effects of drugs</keyword>
  <keyword>Therapeutic uses</keyword>
  <keyword>Clinical Trial, Phase I</keyword>
  <keyword>Immunotherapy, Active</keyword>
  <keyword>CD40 Antigen</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Injections, Intralesional</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

